Fig. 5

Poly-specificity is key for tumor protection. (a) The M2 vaccine delay tumor growth, six mice per group were vaccinated with M2 or left untreated (control) as depicted in the scheme and challenged with MC38 cells on day 59. Tumor growth was significantly reduced in vaccinated mice as compared to the control *p < 0.05 two-way anova bars represent SD. Plots represent value of one out of two experiments. (b) To verify the impact of poly-specificity on tumor growth, the M3 vaccine vector was generated for comparing the M2. M3 expresses, the Reps1 and Adpgk neoantigens, which are in common with M2. Regarding the M3 scheme and vaccination protocol, mice were vaccinated either with the M2 or M3 vector at indicated time points and challenged with MC38 cancer cells (MC38). (c) CD8⁺ immune responses measured in the peripheral blood by FC on day 58 before vaccination. (D) The representative experiment with five mice per group of the tumor challenge started on day 65, the individual growth curve for MC38 cells is depicted for mice vaccinated with control, M3 and M2 vaccine vectors. The experiments were repeated twice with similar results